🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our review on the current state of PARPi development for #prostatecancer is now out in European Urology Oncology - led by Francesca Zacchi + help from several experts in the field sciencedirect.com/science/articl…

Si quieres estar actualizado en cáncer de próstata no te pierdas la 6a edición del curso. Apúntate!

Our last paper is out!. PSMA as a biomarker in mHSPC

Enhorabuena!

PARPi before LuPSMA? Prior PARP inhibitor use is linked to worse LuPSMA outcomes in BRCA2-altered mCRPC. PSA PFS drops from 14 to 2.9 months! ⏳⚠️ Optimal sequencing matters! Emmanuel Antonarakis #ProstateCancer #mCRPC #PSMA #PARPi #Oncology European Urology Oncology Morgan Roupret Elena Castro

What if we screened smarter, not just more? In BARCODE1, men with high polygenic risk (top 10%) had MRI + biopsy— 40% had prostate cancer. Over half needed treatment. Most would’ve been missed by PSA alone. Genetics is rewriting the rules. #ProstateCancer #PrecisionMedicine

Enhorabuena!

Mi despedida a mi padre hoy en todas las ediciones del diario El País: elpais.com/opinion/2025-0…

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials ascopubs.org/doi/abs/10.120…

Piet Ost Congratulations, beautiful achievement. But let me play the devil advocate.... The forest plot shows that in EMBARK patients, with PSMA, "there is always more than what you see", and an ARPI is needed. Your trial is a first warning on the limitations of modern imaging

💚Se acercan días muy especiales para mi 📗”Tu historia no acaba aquí” ya está en librerías. Un libro para acompañar a quienes afrontan un diagnóstico oncológico. Gracias a Plataforma Editorial por creer en este mensaje de esperanza. #oncologiaconalma #lecturarecomendada #esperanza

Revisando el cáncer de próstata con colegas y amigos en Madrid!. Reunión interactiva muy enriquecedora

Enhorabuena! por este proyecto muy necesario para todos los que nos relacionamos con el mundo oncológico

Great session on prostate cancer 💙 with Drs. López Torrecilla & Alongi, moderated by Dr. Henríquez López 👏 🕰️ History of treatment + 💡 Adaptive RT for the future #ProstateCancer #RadiationOncology #AdaptiveRT #Onco25 💥

Allow me to introduce you to Catalonia’s new golf team, which combines the experience of the prostate and golf. The challenges are undeniable, and we are ready to give our best. The future looks promising!!!"

DADSPORT meta-analysis investigated ADT in post-op RT for nonmet prostate cancer ➡️Short or long ADT after postop RT ⬆️ MFS and PCSS. ➡️No clear benefits of OS when ADT is added. ➡️Potential benefit of ADT on OS confined to pts with higher pre-RT PSA sciencedirect.com/science/articl…

📢 Our article on ADT duration + salvage RT in prostate cancer (URONCOR 06-24 trial) is now online! 🧠 Open access for 50 days: 👉 authors.elsevier.com/c/1lUCL_4oIYIT… #ProstateCancer #RadiationOncology #ClinicalResearch #URONCOR0624